Me is to cut 200 jobs in the wake of declining revenues. This company expects a proposed retructuring, affecting 40% of its ...

Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.

CEO Anne Wojcicki told investors on an earnings call Tuesday that the moves are “difficult but necessary actions that we ...

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...

But it’s not just staffing changes: 23andMe is also shutting down its entire therapeutics division, which had been working on ...

23andMe, the struggling ancestry tracing company, continues to spiral, raising questions about its business prospects and what could happen to its sensitive customer genetic testing data. CEO Anne ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0616 GMT – Mega Lifesciences is facing pressure from a ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Last June marked four years since the release of Deloitte Canada's inaugural Reconciliation Action Plan (RAP), the first ...